Biocad To Launch Two Biosimilars In Bosnia-Herzegovina
Forms Part Of Russian Firm's Plans For European Expansion
Russia’s Biocad, with biosimilars already launched in numerous global markets, is continuing to look outward. A focus on territories in south-east Europe has seen the firm receive approvals for two biosimilars in the Balkan country Bosnia and Herzegovina.
You may also be interested in...
The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.
Biotechnology and biosimilars specialist Biocad is seeking to increase its exports by 80% over the next few years as supply agreements for its extensive pipeline begin to deliver and additional manufacturing capacity comes onstream. To this end, the Russian company has recently struck licensing deals with companies in Greece, Mexico and the Middle East and North Africa (MENA) region.
Samsung Bioepis is the latest company to stare down a lawsuit from Genentech over Avastin patents in the US. The Korean firm is aiming to be amongst the early biosimilar movers, after the market formed a year ago.